PL1656949T3 - Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii - Google Patents

Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii

Info

Publication number
PL1656949T3
PL1656949T3 PL05380181T PL05380181T PL1656949T3 PL 1656949 T3 PL1656949 T3 PL 1656949T3 PL 05380181 T PL05380181 T PL 05380181T PL 05380181 T PL05380181 T PL 05380181T PL 1656949 T3 PL1656949 T3 PL 1656949T3
Authority
PL
Poland
Prior art keywords
fibromyalgia
antitrypsin
medicaments
alpha
preparation
Prior art date
Application number
PL05380181T
Other languages
English (en)
Inventor
Blanco Ignacio Blanco
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of PL1656949T3 publication Critical patent/PL1656949T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05380181T 2004-09-24 2005-08-04 Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii PL1656949T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402282A ES2281222B1 (es) 2004-09-24 2004-09-24 Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP05380181A EP1656949B1 (en) 2004-09-24 2005-08-04 Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia

Publications (1)

Publication Number Publication Date
PL1656949T3 true PL1656949T3 (pl) 2007-06-29

Family

ID=35875051

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05380181T PL1656949T3 (pl) 2004-09-24 2005-08-04 Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii

Country Status (15)

Country Link
US (1) US7291595B2 (pl)
EP (1) EP1656949B1 (pl)
JP (1) JP4351663B2 (pl)
CN (1) CN100354000C (pl)
AR (1) AR054210A1 (pl)
AU (1) AU2005203400B2 (pl)
BR (1) BRPI0503821B8 (pl)
CA (1) CA2514816C (pl)
DE (1) DE602005000442T2 (pl)
ES (2) ES2281222B1 (pl)
MX (1) MXPA05008543A (pl)
NZ (1) NZ541743A (pl)
PL (1) PL1656949T3 (pl)
PT (1) PT1656949E (pl)
UY (1) UY29056A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651268T3 (es) * 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
EP2330896B1 (en) * 2008-09-10 2015-11-25 Ben Gurion University Of The Negev Research And Development Authority Antinecrotic activity of alpha 1-antitrypsin
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
MXPA02007187A (es) * 2000-01-25 2002-12-09 Aeropharm Technology Inc Fromulacion medicinal en aerosol.
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
CA2312109A1 (en) * 2000-06-23 2001-12-23 Universite De Sherbrooke Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases

Also Published As

Publication number Publication date
AU2005203400A1 (en) 2006-04-13
PT1656949E (pt) 2007-04-30
JP2006089478A (ja) 2006-04-06
DE602005000442T2 (de) 2007-11-15
BRPI0503821B8 (pt) 2021-05-25
US20060084598A1 (en) 2006-04-20
EP1656949B1 (en) 2007-01-10
HK1083601A1 (zh) 2006-07-07
CA2514816A1 (en) 2006-03-24
AR054210A1 (es) 2007-06-13
ES2281222A1 (es) 2007-09-16
NZ541743A (en) 2005-12-23
BRPI0503821A (pt) 2006-05-09
DE602005000442D1 (de) 2007-02-22
MXPA05008543A (es) 2006-03-28
ES2279498T3 (es) 2007-08-16
JP4351663B2 (ja) 2009-10-28
AU2005203400B2 (en) 2007-01-18
CN1751739A (zh) 2006-03-29
EP1656949A1 (en) 2006-05-17
CA2514816C (en) 2010-12-07
CN100354000C (zh) 2007-12-12
US7291595B2 (en) 2007-11-06
UY29056A1 (es) 2006-02-24
BRPI0503821B1 (pt) 2018-02-06
ES2281222B1 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL183101A (en) Use of tetrahydrocannabivarin in drug production
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL226562A0 (en) Pharmacy combinations containing benzoxazine for the treatment of respiratory diseases
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
IL178816A0 (en) The treatment of childhood asthma
TWI369210B (en) Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies
PL1670482T5 (pl) Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
ZA200806949B (en) Medicinal formulation for the treatment for hepatitis C
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
PL1656949T3 (pl) Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii
GB0415181D0 (en) Compounds for use in the treatment of infection
HU0500145D0 (en) Composition for the treatment of oral diseases
EP1737475A4 (en) VEGETABLE THERAPY FOR THE TREATMENT OF ASTHMA
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
ZA200606780B (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
SI1670482T2 (sl) Uporaba ciklezonida za zdravljenje respiratornih bolezni
AU2004903986A0 (en) Compounds for the Treatment of Vascular Diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases